Kestra Medical Q3 FY26 revenue $24.6M (+63% YoY); FY26 guidance raised to $93M

KESTRA MEDICAL TECHNOLOGIES, LTD.

2026-Q3 EPS reported -$1.76 revenue$66,488,000

Revenue of $24.6M, up 63% YoY; gross margin expanded to 52.6% from 43.4%.
Prescriptions written for ASSURE system up 58% to 5,462; driven by market share gains.
GAAP net loss widened to $34.2M vs $21.8M; adjusted EBITDA loss $21.2M vs $16.3M.
FY26 revenue guidance increased to $93M, representing 55% growth over FY25.
Cash and equivalents $291M after December 2025 equity offering of 6.9M shares.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

KESTRA MEDICAL TECHNOLOGIES, LTD. reported the third quarter fiscal 2026, which ended January 31, 2026 results: revenue $24.6 million, net income $34.2 million. Guidance raised.

Period: the third quarter fiscal 2026, which ended January 31, 2026
Revenue: $24.6 million
Net income: $34.2 million
Guidance: raised
Result: reported results

Exact text from the filing

and digital healthcare company, today reported financial results for the third quarter fiscal 2026, which ended January 31, 2026. Financial Highlights • Generated revenue of $24.6 million in Q3 FY26, an increase of 63% compared to the prior year period. • Expanded gross margin to 52.6% in Q3 FY26 compared to 43.4% in the prior year period. • Increased FY26 revenue

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

KESTRA MEDICAL TECHNOLOGIES, LTD. filing history →

Source: SEC EDGAR

accession 0001193125-26-110720

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.